Qiagen N.V. (QGEN): Cost of Revenue
$790.50M
Year ended 2025-12-31
+1.5%
3-year compound annual growth
+4.4%
5-year compound annual growth
+5.7%
10-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $790.50M | -21.8% | 2026-03-20, From 2025-01-01 |
| 2024-12-31 | $1.01B | +38.2% | 2026-03-20, From 2024-01-01 |
| 2023-12-31 | $731.62M | -3.3% | 2026-03-20, From 2023-01-01 |
| 2022-12-31 | $756.96M | -5.5% | 2025-03-31, From 2022-01-01 |
| 2021-12-31 | $800.84M | +25.6% | 2024-03-11, From 2021-01-01 |
| 2020-12-31 | $637.63M | +22.3% | 2023-03-13, From 2020-01-01 |
| 2019-12-31 | $521.16M | +4.0% | 2022-03-14, From 2019-01-01 |
| 2018-12-31 | $500.89M | +1.2% | 2021-03-05, From 2018-01-01 |
| 2017-12-31 | $494.98M | +0.3% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $493.34M | +8.6% | 2019-03-06, From 2016-01-01 |
| 2015-12-31 | $454.33M | -5.3% | 2018-03-06, From 2015-01-01 |
| 2014-12-31 | $479.57M | -1.4% | 2017-03-06, From 2014-01-01 |
| 2013-12-31 | $486.49M | +13.0% | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | $430.43M | +2.5% | 2015-03-02, From 2012-01-01 |
| 2011-12-31 | $419.94M | +12.9% | 2014-03-03, From 2011-01-01 |
| 2010-12-31 | $371.87M | +8.5% | 2013-03-04, From 2010-01-01 |
| 2009-12-31 | $342.75M | +16.9% | 2012-03-27, From 2009-01-01 |
| 2008-12-31 | $293.29M | n/a | 2011-03-21, From 2008-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Qiagen N.V. (QGEN) | 2025-12-31 | $790.50M | -21.8% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $868.00M | -40.7% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $83.70M | +9.8% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $52.10M | +53.2% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $228.77M | +43.5% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $415.97M | -3.1% |
| Novavax Inc (NVAX) | 2025-12-31 | $73.04M | -64.0% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $19.07M | +55.5% |
| Repligen Corp (RGEN) | 2025-12-31 | $352.01M | -2.2% |
Compare QGEN, MRNA, EXEL, NBIX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗